

CLAIMS

1. Paroxetine maleate in which the ratio of paroxetine to maleic acid (by mole) is 1:1.
- 5 2. Paroxetine maleate in which the ratio of paroxetine to maleic acid (by mole) is 2:1.
3. A compound according to claim 1 or 2 in non-crystalline form.
4. A compound according to claim 1 or 2 in crystalline form.
- 10 5. Paroxetine (1:1) maleate Form A having a melting point of 139-141°C and having an IR or XRD spectrum substantially as disclosed in Example 1.
6. Paroxetine (1:1) maleate Form B having a melting point of 136-138°C and having
15 an IR or XRD spectrum substantially as disclosed in Example 2.
7. A process for the preparation of a compound as claimed in claim 1, 2 or 3 by precipitation from a solution of a paroxetine maleate, spray drying or freeze drying a solution of a paroxetine maleate, evaporating a solution of a paroxetine maleate to a glass,
20 or by vacuum drying of oils of a paroxetine maleate, or solidification of melts of a paroxetine maleate.
8. A process for the preparation of a compound as claimed in claim 1, 2, 4, 5 or 6 by crystallization or recrystallization from a solution of a paroxetine maleate.
- 25 9. A process for preparing paroxetine (1:1) maleate Form A by crystallisation from a solution of paroxetine maleate in ethyl acetate, methanol, ethanol, propan-2-ol, propan-1-ol, sec-butanol, butan-1-ol, methyl isobutylketone, acetone or acetonitrile, or a mixture of solvents, including mixtures with toluene.
10. A process for preparing paroxetine (1:1) maleate Form B by crystallisation from a
30 solution of paroxetine maleate in toluene, or butanone, acetone, dichloromethane or propan-2-ol, or a mixture of one of said solvents with toluene.

11. A process according to claim 9 or 10 in which the solution is seeded with seed crystals of the desired polymorph.
12. A process according to claim 7, 8, 9, 10 or 11 in which the solution, oil or melt of a paroxetine maleate is prepared by treating paroxetine free base or an organic acid salt thereof with maleic acid or an ammonium or amine salt thereof.
13. A process for preparing paroxetine (1:1) maleate Form B in which a solution of paroxetine free base, which is the final stage of a process for manufacturing paroxetine, is treated with maleic acid, and Form B is crystallised from said solution.
14. A process according to claim 13, in which the paroxetine free base, or the resultant maleate is in solution in toluene, or in a solvent mixture containing toluene,
15. A method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.